ASC Therapeutics Doses First Patient with ASC618 Second-Generation Gene Therapy for Hemophilia A
Transformational in-vivo AAV gene therapy for hemophilia A Efficiently biosynthesized and secreted bioengineered factor VIII Potentially leads to lower therapeutic dose, reduced cost, and extended durability ASC Therapeutics, pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies for hematologic and other rare disorders, today announced that the first patient has … Read more